Effect Of A Series Of Novel Sulphonylthioureas On Glucose Tolerance In The Obese fa/fa Zucker Rat
Authors:
- 11 May 2001
- journal article
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 28 (5-6) , 386-391
Abstract
1. The recent development of a series of novel KATP channel modulators, namely sulphonylthioureas and sulphonylureas, is thought to make improvements in potency and tissue selectivity compared with current sulphonylureas, such as glibenclamide, which shares a similar structure to the novel compounds. 2. These novel compounds were first examined for their effect on hyperglycaemia and glucose tolerance during an oral glucose tolerance test following 5 days administration in the lean fa/- and obese fa/fa Zucker rat (a model of insulin resistance). Comparisons with present antidiabetic agents, metformin and glibenclamide were performed. 3. Several compounds showed improvements in glucose tolerance compared with control and the primary structural prerequisites for the maintenance of this activity were investigated. Of most interest was compound 3-15 ((N-[(4-methylphenylsulphonyl]-N'-(2-ethoxypyrid-4-yl)thiourea; 0.1 mg/kg per day), which significantly improved glucose tolerance following 5 days administration in the fa/fa Zucker rat. This paralleled the improvement seen in metformin (300 mg/kg per day)-treated fa/fa rats, but compound 3-15 was up to 3000-fold more potent than metformin. 4. Obese fa/fa Zucker rats were then treated with compound 3-15 for 28 days to determine whether glycaemic control could be maintained over the longer term. 5. Compound 3-15 showed a significant improvement in glucose clearance and reduction in insulin concentration following 28 days treatment during an intravenous glucose tolerance test compared with untreated rats, without any change in the rate of weight gain. 6. The novel sulphonylthiourea 3-15 appears to improve glucose clearance during acute and chronic treatment in the fa/fa Zucker rat with no effect on the rate of weight gain. It is thought that compound 3-15 may be eliciting its actions by improving insulin sensitivity, but its effects on insulin secretion are still to be elucidated.Keywords
This publication has 14 references indexed in Scilit:
- Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug AdministrationAmerican Journal of Gastroenterology, 2000
- Glycemic Control With Diet, Sulfonylurea, Metformin, or Insulin in Patients With Type 2 Diabetes MellitusProgressive Requirement for Multiple Therapies (UKPDS 49)JAMA, 1999
- Metformin Prevents Weight Gain by Reducing Dietary Intake During Insulin Therapy in Patients with Type 2 Diabetes MellitusDrugs, 1999
- The Antihyperglycaemic Effect of MetforminDrugs, 1999
- Troglitazone enhances differentiation, basal glucose uptake, and Glut1 protein levels in 3T3-L1 adipocytes.Endocrinology, 1996
- Metformin: a new oral biguanideClinical Therapeutics, 1996
- Rat Inwardly Rectifying Potassium Channel Kir6.2: Cloning, Electrophysiological Characterization, and Decreased Expression in Pancreatic Islets of Male Zucker Diabetic Fatty RatsBiochemical and Biophysical Research Communications, 1996
- Effects of metformin treatment on glucose transporter proteins in subcellular fractions of skeletal muscle in (fa/fa) Zucker ratsBritish Journal of Pharmacology, 1995
- Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profilesEuropean Journal of Clinical Pharmacology, 1991
- Comparison of glycogen store in rats and guinea-pigs: Effects of anaesthesia, fasting and re-feedingComparative Biochemistry and Physiology Part B: Comparative Biochemistry, 1981